A study of lurbinectedin in combination with atezolizumab compared with atezolizumab as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) following first-line induction therapy with carboplatin, etoposide and atezolizumab

Prior treatment

• Planned consolidative chest radiation
• Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, or lurbinectedin or trabectedin

Other illness

• Presence or history of CNS metastases
• History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
• Disease progression following induction treatment

Other

• Uncontrolled pleural effusion, pericardial effusion or ascites requiring recurrent drainage procedures

• Histologically or cytologically confirmed ES-SCLC (per the VALG staging system)
• Adequate hematologic and end-organ function
• ECOG PS 0 or 1
• No prior systemic treatment for ES-SCLC
• Ongoing response or stable disease per RECIST v1.1 after completion of the induction therapy
• Toxicities attributed to prior induction anti-cancer therapy or PCI resolved to Grade 1 or better